SL
SVB Leerink Latest Price Targets & Analyst Ratings
| Stock | Analyst | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|---|
151
Travere Therapeutics
TVTX
$1.93B
|
JS
Joseph Schwartz
| $21.64 | $38 |
76%
upside
| Outperform |
20 Oct ‘22
2 years ago |
|
|
AMRN
152
Amarin Corp
AMRN
$317M
|
RR
Roanna Ruiz
| $15.33 | $40 |
161%
upside
| Market Perform |
19 Oct ‘22
2 years ago |
|
153
LAVA Therapeutics
LVTX
$41.3M
|
DG
Daina Graybosch
| $1.57 | $28 |
1,683%
upside
| Outperform |
27 Sep ‘22
2 years ago |
|
154
Amylyx Pharmaceuticals
AMLX
$910M
|
MG
Marc Goodman
| $10.20 | $50 |
390%
upside
| Outperform |
8 Sep ‘22
3 years ago |
|
|
MOLN
155
Molecular Partners
MOLN
$134M
|
DG
Daina Graybosch
| $3.58 | $8 |
123%
upside
| Market Perform |
29 Aug ‘22
3 years ago |
|
156
Acadia Healthcare
ACHC
$2.19B
|
WM
Whit Mayo
| $23.72 | $103 |
334%
upside
| Outperform |
26 Aug ‘22
3 years ago |
|
157
MoonLake Immunotherapeutics
MLTX
$3.77B
|
TS
Thomas Smith
| $59.44 | $17 |
71%
downside
| Outperform |
25 Aug ‘22
3 years ago |
|
|
BCYC
158
Bicycle Therapeutics
BCYC
$496M
|
JC
Jonathan Chang
| $7.16 | $50 |
598%
upside
| Outperform |
22 Aug ‘22
3 years ago |
|
|
CLYM
159
Climb Bio, Inc. Common Stock
CLYM
$162M
|
MG
Marc Goodman
| $2.39 | $4 |
67%
upside
| Outperform |
16 Aug ‘22
3 years ago |
|
160
Viridian Therapeutics
VRDN
$1.53B
|
MK
Mike Kratky
| $18.72 | $40 |
114%
upside
| Outperform |
15 Aug ‘22
3 years ago |
|
161
RAPT Therapeutics
RAPT
$214M
|
MK
Mike Kratky
| $12.93 | $384 |
2,870%
upside
| Outperform |
11 Aug ‘22
3 years ago |
|
|
AVDL
162
Avadel Pharmaceuticals
AVDL
$1.53B
|
MG
Marc Goodman
| $15.76 | $12 |
24%
downside
| Outperform |
11 Aug ‘22
3 years ago |
|
163
Xenon Pharmaceuticals
XENE
$3.02B
|
MG
Marc Goodman
| $39.21 | $46 |
17%
upside
| Outperform |
11 Aug ‘22
3 years ago |
|
164
Certara
CERT
$1.69B
|
JZ
Joy Zhang
| $10.52 | $26 |
147%
upside
| Outperform |
10 Aug ‘22
3 years ago |
|
165
OptimizeRx
OPRX
$349M
|
JZ
Joy Zhang
| $18.82 | $30 |
59%
upside
| Outperform |
10 Aug ‘22
3 years ago |
|
166
Beam Therapeutics
BEAM
$2.11B
|
RB
Rick Bienkowski
| $20.88 | $113 |
441%
upside
| Outperform |
10 Aug ‘22
3 years ago |
|
167
Revolution Medicines
RVMD
$7.57B
|
JC
Jonathan Chang
| $40.50 | $30 |
26%
downside
| Outperform |
10 Aug ‘22
3 years ago |
|
168
MacroGenics
MGNX
$126M
|
JC
Jonathan Chang
| $2 | $12 |
500%
upside
| Outperform |
9 Aug ‘22
3 years ago |
|
169
GoodRx Holdings
GDRX
$1.39B
|
SD
Stephanie Davis
| $4 | $11 |
175%
upside
| Market Perform |
9 Aug ‘22
3 years ago |
|
170
Celldex Therapeutics
CLDX
$1.52B
|
TS
Thomas Smith
| $22.87 | $64 |
180%
upside
| Outperform |
9 Aug ‘22
3 years ago |
|
171
Castle Biosciences
CSTL
$683M
|
PS
Puneet Souda
| $23.56 | $50 |
112%
upside
| Market Outperform |
9 Aug ‘22
3 years ago |
|
172
Acadia Pharmaceuticals
ACAD
$4.26B
|
MG
Marc Goodman
| $25.26 | $21 |
17%
downside
| Outperform |
9 Aug ‘22
3 years ago |
|
|
PRTC
173
PureTech Health
PRTC
$392M
|
TS
Thomas Smith
| $16.23 | $70 |
331%
upside
| Outperform |
9 Aug ‘22
3 years ago |
|
174
Mersana Therapeutics
MRSN
$34M
|
JC
Jonathan Chang
| $6.82 | $350 |
5,032%
upside
| Outperform |
9 Aug ‘22
3 years ago |
|
175
CRISPR Therapeutics
CRSP
$4.99B
|
RB
Rick Bienkowski
| $54.86 | $107 |
95%
upside
| Outperform |
8 Aug ‘22
3 years ago |
|